title: Absolute peripheral monocyte count at diagnosis predicts central nervous system relapse in diffuse large B-cell lymphoma.
abstract: Recently, elevated peripheral blood monocyte counts at diagnosis have been shown to be an independent marker associated with poor prognosis in patients with both non-Hodgkin and Hodgkin lymphoma. In this study, we retrospectively analyzed the data from a total of 550 patients with diffuse large B-cell lymphoma and evaluated the relationship between central nervous system relapse and absolute monocyte counts at diagnosis. Twenty-six patients developed central nervous system relapse. The central nervous system relapse-free survival rate was significantly lower in patients with the absolute monocyte counts ≥ 0.51 × 10(9)/L (87.8% versus 96.4%; P<0.001). This association was independently significant after adjusting for other significant factors, including systemic relapse as a time-dependent covariate by multivariate analysis (hazard ratio 2.46; 95% confidence intervals 1.05-5.75; P=0.039). These results suggest that the absolute monocyte count at diagnosis is an independent significant risk factor for central nervous system relapse in patients with diffuse large B-cell lymphoma.
authors.affiliation: Department of Hematology and Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research;
authors.forename: Hideaki
authors.initials: H
authors.lastname: Nitta
authors.affiliation: Department of Hematology and Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research;
authors.forename: Yasuhito
authors.initials: Y
authors.lastname: Terui
authors.affiliation: Department of Hematology and Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research;
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yokoyama
authors.affiliation: Department of Hematology and Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research;
authors.forename: Yuko
authors.initials: Y
authors.lastname: Mishima
authors.affiliation: Department of Hematology and Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research;
authors.forename: Noriko
authors.initials: N
authors.lastname: Nishimura
authors.affiliation: Department of Hematology and Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research;
authors.forename: Kyoko
authors.initials: K
authors.lastname: Ueda
authors.affiliation: Department of Hematology and Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research;
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Kusano
authors.affiliation: Department of Pathology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research;
authors.forename: Naoko
authors.initials: N
authors.lastname: Tsuyama
authors.affiliation: Pathology Project for Molecular Targets, The Cancer Institute of the Japanese Foundation for Cancer Research;
authors.forename: Kengo
authors.initials: K
authors.lastname: Takeuchi
authors.affiliation: Division of Hematology, Saitama Medical Center, Jichi Medical University, Japan.
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Kanda
authors.affiliation: Department of Hematology and Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; khatake@jfcr.or.jp.
authors.forename: Kiyohiko
authors.initials: K
authors.lastname: Hatake
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000556:secondary*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000473:pathology*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate